Evidence map›Paper›PMID 35290073›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis.

Ines Vaz-Luis, Antonio Di Meglio, Julie Havas, Mayssam El-Mouhebb, Pietro Lapidari, Daniele Presti, Davide Soldato, Barbara Pistilli, Agnes Dumas, Gwenn Menvielle and 13 more

Registry-linked trialAbstract read
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01993498 (A Prospective Cohort to Investigate Survivorship Issues in Patients With Early Cancer), which is not on this map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01993498 narecruitingnot on this map

A Prospective Cohort to Investigate Survivorship Issues in Patients With Early Cancer

TypeinterventionalSponsorUNICANCERRan2012 to 2034Enrolled14,750ConditionsBreast Cancer Nos Metastatic Recurrent, Early Lung CancerArmsblood sampling
3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Exploring the role of health-related quality of life measures in predictive modelling for oncology: a systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Pooled it
  2. Trial
  3. Trial
  4. Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Financial toxicity trajectories and their association with short-term and long-term health outcomes in Chinese patients with cancer: a prospective cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  11. Heterogeneous trajectory of cancer-related fatigue and its associated factors in patients with glioma during the perioperative period: a prospective longitudinal study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Ines Vaz-LuisGustave Roussy, Medical Oncology, Villejuif, France.ORCID 0000-0002-7194-2260
Antonio Di MeglioGustave Roussy, Medical Oncology, Villejuif, France.ORCID 0000-0002-0233-3189
Julie HavasINSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, University Paris-Saclay, Villejuif, France.
Mayssam El-MouhebbINSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, University Paris-Saclay, Villejuif, France.
Pietro LapidariINSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, University Paris-Saclay, Villejuif, France.
Daniele PrestiINSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, University Paris-Saclay, Villejuif, France.ORCID 0000-0003-4442-6700
Davide SoldatoINSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, University Paris-Saclay, Villejuif, France.ORCID 0000-0002-2090-3245
Barbara PistilliGustave Roussy, Medical Oncology, Villejuif, France.ORCID 0000-0002-9184-7199
Agnes DumasUniversite de Paris, ECEVE UMR 1123, INSERM, Paris, France.ORCID 0000-0001-7948-6952
Gwenn MenvielleSorbonne Université, INSERM, Pierre Louis Institute of Epidemiology and Public Health, Paris, France.ORCID 0000-0002-3261-6366
Cecile CharlesGustave Roussy, Supportive Care, IPLESP, Paris, France.ORCID 0000-0003-3126-1337
Sibille EverhardUNICANCER, Paris, France.ORCID 0000-0002-3151-5707
Anne-Laure MartinUNICANCER, Paris, France.ORCID 0000-0002-9302-8576
Paul H CottuInstitut Curie, Paris, France.ORCID 0000-0001-6434-3932
Florence LereboursInstitut Curie Saint Cloud, Saint Cloud, France.
Charles CoutantCentre Georges-François Leclerc, Dijon, France.
Sarah DauchyGustave Roussy, Supportive Care, IPLESP, Paris, France.
Suzette DelalogeGustave Roussy, Medical Oncology, Villejuif, France.ORCID 0000-0003-2106-9165
Nancy U LinDana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-2263-5413
Patricia A GanzUniversity of California, Los Angeles, CA.ORCID 0000-0002-1841-4143
Ann H PartridgeDana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-4722-4824
Fabrice AndréGustave Roussy, Medical Oncology, Villejuif, France.ORCID 0000-0001-5795-8357
Stefan MichielsService de Biostatistique et d'Epidémiologie, Gustave Roussy, Oncostat U1018, INSERM, University Paris-Saclay, Villejuif, France.ORCID 0000-0002-6963-2968

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFatigue is recognized as one of the most burdensome and long-lasting adverse effects of cancer and cancer treatment. We aimed to characterize long-term fatigue trajectories among breast cancer survivors.

methodsWe performed a detailed longitudinal analysis of fatigue using a large ongoing national prospective clinical study (CANcer TOxicity, ClinicalTrials.gov identifier: NCT01993498) of patients with stage I-III breast cancer treated from 2012 to 2015. Fatigue was assessed at diagnosis and year 1, 2, and 4 postdiagnosis. Baseline clinical, sociodemographic, behavioral, tumor-related, and treatment-related characteristics were available. Trajectories of fatigue and risk factors of trajectory-group membership were identified by iterative estimates of group-based trajectory models.

resultsThree trajectory groups were identified for severe global fatigue (n = 4,173). Twenty-one percent of patients were in the

conclusionOur findings highlight the multidimensional nature of cancer-related fatigue and the complexity of its risk factors. This study helps to identify patients with increased risk of severe fatigue and to inform personalized interventions to ameliorate this problem.

Indexed as

Breast NeoplasmsFatigueFemaleHumansLongitudinal StudiesPatient Reported Outcome MeasuresProspective StudiesQuality of LifeSurvivors

Identifiers

PMID35290073
PMCPMC9242405

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.